Cargando…
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
Lung cancer is relatively rare in young patients as the median age at diagnosis is 65–70 years. The main objective of this nationwide study was to investigate the characteristics of young lung cancer in Taiwan, especially the relationships among smoking behavior, epidermal growth factor receptor (EG...
Autores principales: | Hsu, Chia-Hung, Tseng, Chien-Hua, Chiang, Chun-Ju, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Chen, Kun-Chieh, Wang, Chih-Liang, Chen, Chih-Yi, Yen, Sang-Hue, Chiu, Chao-Hua, Huang, Ming-Shyan, Yu, Chong-Jen, Tsai, Ying-Huang, Chen, Jin-Shing, Tsai, Chun-Ming, Chou, Teh-Ying, Lin, Kuei-Chih, Tsai, Ming-Hsun, Lee, Wen-Chung, Ku, Hsiu-Ying, Liu, Tsang-Wu, Yang, Tsung-Ying, Chang, Gee-Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216823/ https://www.ncbi.nlm.nih.gov/pubmed/27191886 http://dx.doi.org/10.18632/oncotarget.9338 |
Ejemplares similares
-
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017) -
Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023) -
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018) -
Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023) -
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)